scholarly journals Circulating Tumor DNA Testing for Liver Cancer

2015 ◽  
Vol 1 (5) ◽  
pp. 458-459 ◽  
Author(s):  
Larissa V. Furtado ◽  
Jeremy P. Segal
Keyword(s):  
Liver Cancer ◽  
Circulating Tumor Dna ◽  
Dna Testing ◽  
Tumor Dna

scholarly journals Using Cell Free DNA Reference Standards to Evaluate the Analytical Performance of Circulating Tumor DNA Testing and Solid Organ Transplant Health Surveillance

BioTechniques ◽  
2015 ◽  
Vol 59 (4) ◽  
Author(s):  
Hadas Amit ◽  
Shen Wei ◽  
Javier Armisen-Garrido ◽  
Bernice Edgeworth ◽  
Robert Woodward ◽  
...  
Keyword(s):  
Organ Transplant ◽  
Circulating Tumor Dna ◽  
Solid Organ Transplant ◽  
Health Surveillance ◽  
Analytical Performance ◽  
Solid Organ ◽  
Dna Testing ◽  
Cell Free Dna ◽  
Free Dna ◽  
Tumor Dna

scholarly journals The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time

2020 ◽  
Vol 9 (1) ◽  
pp. BMT34 ◽  
Author(s):  
Kevin M Koo ◽  
Paul N Mainwaring
Keyword(s):  
Breast Cancer ◽  
Circulating Tumor Dna ◽  
Prime Time ◽  
Dna Testing ◽  
Liquid Biopsies ◽  
Tumor Dna

scholarly journals Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas

2019 ◽  
Vol 10 (3) ◽  
pp. 400-406 ◽  
Author(s):  
Madiha Iqbal ◽  
Ali Roberts ◽  
Jason Starr ◽  
Kabir Mody ◽  
Pashtoon Murtaza Kasi
Keyword(s):  
Circulating Tumor Dna ◽  
Dna Testing ◽  
Clinical Value ◽  
Gastric Adenocarcinomas ◽  
Tumor Dna

scholarly journals Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence

2019 ◽  
Vol 9 ◽  
Author(s):  
Aixa E. Soyano ◽  
Candice Baldeo ◽  
Pashtoon M. Kasi
Keyword(s):  
Pancreas Cancer ◽  
Cancer Recurrence ◽  
Circulating Tumor Dna ◽  
Dna Testing ◽  
Tumor Dna

Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1514-1514 ◽  
Author(s):  
Thomas Paul Slavin ◽  
Kimberly Banks ◽  
Darya Chudova ◽  
Geoffrey R. Oxnard ◽  
Justin I. Odegaard ◽  
...  
Keyword(s):  
Point Mutations ◽  
Read Depth ◽  
Circulating Tumor Dna ◽  
Tumor Burden ◽  
Hereditary Cancer Syndrome ◽  
Dna Testing ◽  
Sequencing Data ◽  
Advanced Cancer Patients ◽  
Cancer Syndrome ◽  
Tumor Dna

1514 Background: No studies have yet described incidental detection of germline cancer predisposition mutations using circulating cell-free DNA (cfDNA). Methods: Deidentified cfDNA sequencing data from 10288 advanced cancer patients (pts) undergoing clinical circulating tumor DNA testing (Guardant360, 73 genes) were included in this study. CfDNA was extracted from plasma and quantified. A DNA library was prepared and sequenced to 15,000X average read depth. Using Ingenuity Variant Analysis, point mutations and small indels suspicious for germline origin (allele fraction 40-60%) were classified following American College of Medical Genetics and Genomics guidelines. Results: More than 50 cancer types were studied, including lung (40%), breast (20%), CRC (8%), prostate (6%), and pancreas (3%). Average age was 63.6 years (range:18-95), 42% were male. Of 34,873 putative germline variants identified, 520 (1.5%) were pathogenic or likely pathogenic (PV), 16,939 (49%) were of uncertain significance, and 17,414 (50%) were benign or likely benign. Of the 250 pts (2.4%) with hereditary cancer syndrome gene PVs, 83 were excluded due to high level of somatic tumor burden leaving 167 (1.6%) with putative germline PVs; rates were higher in pts <50 vs >50 overall (3.3% vs 1.4%, p=0.02) and in breast cancer pts (4.3% vs 1.5%, p=0.03). Conclusions: The observed frequency of incidentally identified putative germline PVs is expectedly lower than the true germline rate; however, these findings illustrate that detection from cfDNA is clinically feasible. Importantly, incidental germline findings could impact oncology treatment planning (e.g. PARP inhibitors for BRCA1/2 mutations) and could benefit families via increased surveillance/primary prevention. Further research is needed to explore how to report potential germline results to clinicians using a systems-based approach. [Table: see text]

Perioperative circulating tumor DNA analysis to predict patient prognosis in liver cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4593-4593
Author(s):  
Ledu Zhou ◽  
Ying Xu ◽  
Dong Wang ◽  
Ke Ye ◽  
Liang Xiao ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Survival Time ◽  
Disease Free Survival ◽  
Circulating Tumor Dna ◽  
Rank Test ◽  
Free Survival ◽  
Log Rank Test ◽  
Post Operation ◽  
Disease Free ◽  
Tumor Dna

4593 Background: Resection is a major method for early-stage liver cancer patients. Unfortunately, there still a few patients with post-operation recurrences. Circulating tumor DNA (ctDNA) had been reported as a biomarker in reflecting tumor load and treatment efficacy in some cancer species. Here, we report an application of ctDNA in the perioperative period of liver cancer using targeted sequencing with a 1021-gene panel. Methods: 97 patients diagnosed with liver cancer were enrolled in this study. Postoperative peripheral blood samples were collected within 7 days after surgery and analyzed using hybridization capture based NGS ERSeq method from all patients. Whether a mutant gene was detected in the peripheral blood was defined as ctDNA(+) and ctDNA(-), respectively. Results: Multivariate Cox analysis showed that the post-operation ctDNA was an independent poor prognostic predictor (AFP, RR: 1.0002, 95% Cl: 1.0001-1.0002; ctDNA, RR: 3.738, Cl: 1.872-7.691). 21 patients were ctDNA(+), and all of them had recurrenced (21/21, 100%), while 76 patients were ctDNA(-), and only 12 (12/76, 15.8%) patients had recurrenced. The median disease-free survival time was 5.0 months in ctDNA(+) group and the ctDNA(-) group had not reach the median time (Log-rank test, P < 0.0001). ctDNA combined with AFP would effectively predict the prognosis of patients after surgery. AFP(H) ( > = 400 ng/mL) and ctDNA(+) patients have the worst prognosis and all of the patients had relapsed, while AFP(L) ( < 400 ng/mL) and ctDNA(-) patients had the best prognosis, with less than 20% of patients had relapsed (Log-rank test, P < 0.0001). The median disease-free survival time was 2.0, 6.0 and 7.0 months in ctDNA(+)-AFP(H) (n = 8), ctDNA(-)-AFP(H) (n = 30) and ctDNA(+)-AFP(L) (n = 13) groups, respectively, while ctDNA(-)-AFP(L) group (n = 46) had not reach the median time statistically (Log-rank test, P = 0.0364). Conclusions: In summary, Perioperative ctDNA detection has great potential value clinically, and it also suggests that patients with positive ctDNA after surgery should receive some adjuvant treatments as soon as possible to improve the survival time.

Mutational profiles and amplifications on circulating tumor DNA testing in patients with young-onset colorectal cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15067-e15067
Author(s):  
Saivaishnavi Kamatham ◽  
Dorin Colibaseanu ◽  
Amit Merchea ◽  
Faisal Shahjehan ◽  
Pashtoon Murtaza Kasi
Keyword(s):  
Colorectal Cancer ◽  
Age Distribution ◽  
Circulating Tumor Dna ◽  
Rectal Tumors ◽  
Dna Testing ◽  
Wild Type ◽  
Young Onset ◽  
Rectal Cancers ◽  
Tumor Dna ◽  
Selection Of

e15067 Background: There has been a concerning rise of colorectal cancer (CRC) in young individuals (<50 years). There appears to be a preponderance of left-sided tumors and rectal cancers, however, the etiology and biology is not entirely known. Our aim was to describe the results of circulating tumor DNA based (ctDNA) testing in young-onset CRC. Methods: We studied the results of 186 patients with CRC who had ctDNA testing, of whom 41 (22%) had young-onset CRC from January 2017 to January 2019 at Mayo Clinic, Florida. They were categorized based on their age at diagnosis. Results: The age distribution and the aberrations seen are summarized in the table. 25 (61%) were left sided, 9 (22%) were right sided, 7 (17%) were rectal tumors. ctDNA testing was able to identify mutations in 4 (9.8%) patients with BRAFV600E, 8 (19.5%) with RAS and categorized 29 (70.7%) as RAS/RAF wild-type. Furthermore, amplifications were detected in MYC 6 (14.6%) , MET 3 (7.3%) and ERBB2 1 (2.4%). 3(7.3%) were MSI-High and there were 4 individuals with BRCA1/2 noted on ctDNA testing. Conclusions: ctDNA testing for young onset CRC is feasible and identifies a spectrum of clinically meaningful and actionable aberrations. These can further be of use to evaluate treatment response, progression or help in selection of clinical trials. [Table: see text]

scholarly journals Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer

2020 ◽  
Vol 11 (5) ◽  
pp. 1065-1077
Author(s):  
Wei Zhao ◽  
Lige Qiu ◽  
Huajiang Liu ◽  
Ying Xu ◽  
Meixiao Zhan ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Predictive Biomarker ◽  
Interventional Therapy ◽  
Circulating Tumor Dna ◽  
Tumor Dna

scholarly journals 675 Utility of circulating tumor DNA testing in Merkel cell carcinoma patients

2021 ◽  
Vol 141 (5) ◽  
pp. S117
Author(s):  
T. Akaike ◽  
C. Doolittle-Amieva ◽  
K. Lachance ◽  
A.S. Fonseca ◽  
C. Church ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Circulating Tumor Dna ◽  
Merkel Cell ◽  
Dna Testing ◽  
Tumor Dna

Circulating tumor DNA testing in advanced non-small cell lung cancer

Lung Cancer ◽  
2018 ◽  
Vol 119 ◽  
pp. 42-47 ◽  
Author(s):  
Everett J. Moding ◽  
Maximilian Diehn ◽  
Heather A. Wakelee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Dna Testing ◽  
Small Cell Lung ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document